Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G P Tonini

Showing results (71-80 of 75) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 75 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1997
MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 childrenG P Tonini, L Boni, A Pession, et al.
British Journal of Cancer|September 15, 2012
Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG projectG Schleiermacher, V Mosseri, W B London, et al.
British Journal of Cancer|October 31, 2014
Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplificationR Defferrari, K Mazzocco, I M Ambros, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2003
Quality assessment of genetic markers used for therapy stratificationI M Ambros, J Benard, M Boavida, et al.
British Journal of Cancer|December 8, 2011
Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study)G Schleiermacher, J Michon, A Ribeiro, et al.
Pageof 8

Showing results (71-80 of 75) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 75 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1997
MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 childrenG P Tonini, L Boni, A Pession, et al.
British Journal of Cancer|September 15, 2012
Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG projectG Schleiermacher, V Mosseri, W B London, et al.
British Journal of Cancer|October 31, 2014
Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplificationR Defferrari, K Mazzocco, I M Ambros, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2003
Quality assessment of genetic markers used for therapy stratificationI M Ambros, J Benard, M Boavida, et al.
British Journal of Cancer|December 8, 2011
Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study)G Schleiermacher, J Michon, A Ribeiro, et al.
Pageof 8